TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07604285: A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma

Sponsor: Myosin Therapeutics Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$5,222,910

Rescue Site Savings

+$3,455,760

Unlock Full NCT07604285 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07604285 Rescue Dossier →